I spoke to my colleagues in the policy and campaigns team, and they wished to respond on this thread to give an update on the current situation with Enhertu and what we’ve been doing to try and make sure people can access it on the NHS.
Hopefully this answers some of the questions people have asked. Let us know if there’s more you’d like to know.
To start, we’d like to explain who Enhertu is for and also what HER2-low is. Enhertu is a targeted treatment for certain patients with HER2-low secondary breast cancer, which could be life-extending. HER2-low is a new classification for people with low levels of HER2 expression (which is defined by a score of IHC 1+ or IHC2+/ISH-).
It is estimated that around 50% of all breast cancers show low levels of HER2. Enhertu is already available for use on the NHS in Scotland, but disappointingly, Enhertu (trastuzumab deruxtecan) was provisionally rejected for use on the NHS in England last September.
You can find our response to his here: We respond to provisional rejection of secondary breast cancer drug for use on NHS in England | Breast Cancer Now
To help reverse the decision, we have been in direct contact with both NICE and Daiichi Sankyo to encourage them to work together to find a solution, and make the drug available for patients with HER-low secondary breast cancer. We have also responded to the NICE consultation, including comments from women with HER2-low secondary breast cancer, setting out what access to the drug would mean for them.
We also encouraged women who could potentially benefit from the drug to respond to NICE’s consultation directly.
In December, NICE announced a pause in the process to enable negotiations between NHS England and Daiichi Sankyo and since this pause was announced, we have continued to hold meetings with both parties to stress the importance of quickly reaching a deal.
In January we shared this open letter from women with HER2-low secondary breast cancer to NHS England and Daiichi Sankyo. Open letter to NHS England and Daiichi Sankyo | Breast Cancer Now
We’ll continue doing everything we can to ensure that we get a positive resolution.